Coriell Institute for Medical Research

Coriell Institute for Medical Research
Name	Coriell Institute for Medical Research
Formation	1953
Type	Nonprofit biomedical research institute
Headquarters	Camden, New Jersey
Leader title	President & CEO
Leader name	Eric D. Green
Region served	United States

Contents

Coriell Institute for Medical Research is an independent nonprofit biomedical research organization based in Camden, New Jersey with a long history of contributions to human genetics, biobanking, and translational services. The institute operates large-scale cell repositories, clinical testing laboratories, and research programs that intersect with institutions such as National Institutes of Health, Centers for Disease Control and Prevention, and academic centers including University of Pennsylvania and Rutgers University. Its collections and services support studies by investigators at organizations like Broad Institute, Cold Spring Harbor Laboratory, and Massachusetts General Hospital.

History

Founded in 1953, the institute emerged amid postwar expansion of biomedical infrastructure associated with entities such as National Institutes of Health and initiatives led by figures from Rockefeller University and Salk Institute for Biological Studies. Early work included cytogenetics and cell culture contributions paralleling advances at Cold Spring Harbor Laboratory and Johns Hopkins University. Over decades it established repositories and collaborated with projects like the Human Genome Project, consortia associated with Wellcome Trust, and epidemiologic programs at Harvard University and Yale University. The institute’s archive of cell lines and genetic materials attracted partnerships with biobanks at Mayo Clinic, Fred Hutchinson Cancer Center, and international biorepositories in coordination with agencies such as European Molecular Biology Laboratory.

The institute’s mission emphasizes human genetics research, precision medicine, and translational support similar to initiatives at National Human Genome Research Institute, Howard Hughes Medical Institute, and European Molecular Biology Laboratory. Programmatic areas have included population genomics projects aligned with studies from 1000 Genomes Project, pharmacogenomics collaborations paralleling work at Stanford University School of Medicine and University of California, San Francisco, and rare disease research in concert with organizations like Undiagnosed Diseases Network and Global Genes. Investigators at the institute collaborate with clinical centers including Children's Hospital of Philadelphia and Cleveland Clinic to study genotype–phenotype correlations and biomarker development.

The institute maintains extensive biorepositories, including lymphoblastoid cell lines, primary fibroblasts, and DNA samples used by researchers at Broad Institute, Sanger Institute, and European Bioinformatics Institute. Its repository architecture supports large-scale data sharing consistent with standards promoted by Global Alliance for Genomics and Health and best practices from International Society for Biological and Environmental Repositories. Collections have been utilized in studies involving cohorts from Framingham Heart Study, NCI's Cancer Genome Atlas, and population initiatives like UK Biobank. The repository provides specimen access to investigators from institutions such as Columbia University, Duke University, and University of California, Los Angeles for work on cancer, neurodegeneration, and rare genetic disorders.

The institute offers clinical laboratory services, genetic testing, and translational support aligned with regulatory frameworks from Food and Drug Administration and accreditation by organizations like College of American Pathologists. Its testing programs address pharmacogenetics, cytogenetics, and molecular diagnostics used in care settings at Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Mount Sinai Health System. The institute partners with industry entities such as Thermo Fisher Scientific, Illumina, and Roche for assay development, and with clinical networks including All of Us Research Program and regional health systems for implementation science in precision medicine.

Educational initiatives target researchers, clinicians, and the public, drawing on models from Smithsonian Institution and academic outreach programs at Massachusetts Institute of Technology and University of Pennsylvania. The institute engages in bioethics discourse with scholars from Harvard Medical School and policy centers like Johns Hopkins Berman Institute of Bioethics on topics including consent, data sharing, and return of results, echoing debates involving entities such as Wellcome Trust and European Commission advisory bodies. Outreach includes workshops, training for laboratory personnel in collaboration with American Society of Human Genetics and public-facing materials for patient advocacy groups like Parent Project Muscular Dystrophy and CureDuchenne.

Governance comprises an independent board and leadership that collaborate with funders including National Institutes of Health, philanthropic organizations like Gordon and Betty Moore Foundation and Bill & Melinda Gates Foundation, and corporate partners such as Pfizer and GlaxoSmithKline. Strategic partnerships extend to academic consortia at Rutgers University, clinical networks at University of Pennsylvania Health System, and international research infrastructures including European Molecular Biology Laboratory and Wellcome Sanger Institute. Funding streams historically include federal grants from National Institutes of Health, contract work for agencies like Centers for Disease Control and Prevention, and philanthropic support from foundations such as Robert Wood Johnson Foundation.

Category:Biomedical research institutes